Ergoteles’s Greenwich LifeSciences GLSI Stock Holding History

Ergoteles’s Portfolio GLSI Stock Details GLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-20,000	Closed	-$169K	–	1703
2022 Q2	$169K	Buy	+20,000	New	+$229K	0.01%	1386

Other funds holding GLSI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ergoteles's GLSI Position: Q3 2022 in Review

Ergoteles sold out of Greenwich LifeSciences (GLSI) in Q3 2022, closing a stake of 20,000 shares — an estimated $169K sold.

Ergoteles first reported a position in GLSI in Q2 2022 and held it in 1 quarter. The position peaked at $169K in Q2 2022. 21 funds tracked by Wall St. Rank hold GLSI as of Q3 2022.

Ergoteles reported no remaining Greenwich LifeSciences position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 20,000 Greenwich LifeSciences shares in Q3 2022, an estimated $169K.
Ergoteles first reported a position in Greenwich LifeSciences in Q2 2022 and held it in 1 quarter.
Ergoteles's Greenwich LifeSciences position peaked at $169K in Q2 2022.
21 funds tracked by Wall St. Rank held Greenwich LifeSciences as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.